Ionis Pharmaceuticals, Inc. (IONS) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ionis Pharmaceuticals, Inc. (IONS:NASDAQ), powered by AI.

Current Price
$73.09
P/E Ratio
-30.7
Market Cap
11.7B
Sector
Healthcare
What is the Ionis Pharmaceuticals, Inc. stock price forecast?

Ionis Pharmaceuticals, Inc. is currently trading at $73.09. View real-time AI analysis on Alpha Lenz.

What is Ionis Pharmaceuticals, Inc. insider trading activity?

View the latest insider trading data for Ionis Pharmaceuticals, Inc. on Alpha Lenz.

What is Ionis Pharmaceuticals, Inc.'s P/E ratio?

Ionis Pharmaceuticals, Inc.'s P/E ratio is -30.7.

Ionis Pharmaceuticals, Inc.

NASDAQ · IONS
$73.09-0.87(-1.18%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Ionis Pharmaceuticals, Inc.'s future dividend policy...
Alpha Chat Insight

Ionis Pharmaceuticals, Inc. trades at a P/E of -30.7 (undervalued) with modest ROE of -70.8%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.

Ask for details

Company Overview

Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in the discovery and development of human therapeutic drugs through the use of antisense technology. Founded in 1989 and headquartered in Carlsbad, California, Ionis is recognized for pioneering precision medicines that target RNA to modulate gene expression, addressing a variety of unmet medical needs. The company’s drug development pipeline spans several therapeutic areas, with a focus on severe and rare diseases, neurological disorders, and cardiovascular conditions. Notable for its significant investment in research and development, Ionis’s approach allows for the creation of novel therapies that might not be achievable through traditional pharmaceutical methods. In the broader financial market, Ionis Pharmaceuticals plays a key role within the health technology sector, representing innovative advancements in biotechnology and contributing to the progress of genomics-driven medicine. With a workforce of over 1,000 employees, Ionis continues to impact the healthcare landscape by advancing new treatment options for patients globally.

CEODr. Brett P. Monia Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees1,069

Company Statistics

FY 2025

Profile

$11.69BMarket Cap
$943.71MRevenue
0.00Shares Out
1,069Employees

Margins

98.31%Gross
-40.33%EBITDA
-40.45%Operating
-40.22%Pre-Tax
-40.41%Net

Valuation

-30.66P/E
23.91P/B
12.39EV/Sales
-35.17EV/EBITDA
-35.91P/FCF

Growth (CAGR)

17.12%Rev 3Yr
5.29%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-11.69%ROA
-70.80%ROE
-9.05%ROIC

Financial Health

$372.26MCash & Cash Equivalents
$2.66BNet Debt
620.49%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Ionis Pharmaceuticals, Inc. (ticker: IONS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 1,069 employees. Market cap is $11.7B.

The current price is $73.09 with a P/E ratio of -30.66x and P/B of 23.91x.

ROE is -70.80% and operating margin is -40.45%. Annual revenue is $944M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Ionis Pharmaceuticals, Inc. (IONS) Stock Forecast 2026 $73.09 — Price, Financials & Analyst Targets | Alpha Lenz